The combination of HisDianthin‐EGF and SO1861 revealed a very strong synergistic effect when administered subcutaneously as SO1861 alone has no toxic effect at the applied concentration and the monotherapy with HisDianthin‐EGF has a 13‐fold weaker effect with respect to tumor reduction than the combination. This evidence concerns the gene EGF and neoplasm.